SecBot SecBot
144 ·Filed Apr 15, 2026

ORKA

Oruka Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago SEC0001950047-26-003530
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

The sale is pre-planned under a 10b5-1 arrangement, reducing immediate negative signal; however, traders should monitor for follow-through sales and assess whether additional insider selling follows, which could indicate broader sentiment.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$67.07
T+0 close · Apr 15, 2026 · via day close
Latest settled
+26.08%
T+60 · $84.56
Vs SPY
+19.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 16 $67.07entry
  2. T+1 · 7mo ago +2.76%α +1.54% · $68.92
  3. T+5 · 7mo ago +1.00%α +0.02% · $67.74
  4. T+20 · 6mo ago −5.80%α −11.62% · $63.18
  5. T+60 · 4mo ago +26.08%α +19.03% · $84.56
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Joana Goncalves, an officer of Oruka Therapeutics, filed a Form 144 to notify intent to sell up to 21,000 shares of common stock received from exercised stock options. The sale is part of a pre-arranged 10b5-1 plan and follows prior sales in February and March 2026.

Key Facts

  • Joana Goncalves, an officer at Oruka Therapeutics, filed Form 144 for the proposed sale of 21,000 shares.
  • The shares were acquired through the exercise of stock options and are being sold under a 10b5-1 plan.
  • Prior sales occurred on February 17, 2026 (7,000 shares) and March 16, 2026 (7,641 shares), totaling over 14,000 shares sold or proposed for sale recently.
  • The filing date is April 15, 2026, with the underlying options exercised on that date.

Financial Impact

Approximately $1.41 million based on the reported value of $1,408,260 for 21,000 shares, or about $67.06 per share.

dilutioninsider ownership

Risk Factors

  • Perception of insider selling pressure, especially following recent transactions.
  • Potential downward price pressure if the full 21,000 shares are sold rapidly.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-003530
Document: 0001950047-26-003530-index.html0001950047-26-003530
Document: 0001950047-26-003530.txt0001950047-26-003530

Track record

40 reports on ORKA

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
  3. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
  4. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
  5. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  6. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  7. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
  8. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  9. Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  10. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
Showing 10 of 40

US Market Status

Market Closed · Opens in 8h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 15, 2026